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This study reports the use of lamotrigine, largely as add-on therapy, in 34 children, adolescents and adults with 
brain damage and resistant seizures. Seventy-four percent of the patients howed a greater than 50% improvement 
in seizure control with 35% becoming seizure free. This improvement in seizure control was associated with an 
enhanced quality of life in 65% of the patients as assessed by improved alertness, mobility, speech and 
independence. It was possible to reduce 36% of the pre-existing antiepileptic drugs and the side effect profile of 
lamotrigine was very good. It is proposed that lamotrigine may be a particularly useful antiepileptic drug in this 
particular group of patients. 
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INTRODUCTION 
Lamotrigine has been found to be helpful in a 
substantial number of children and adults with 
difficult epilepsy 1-4 including both partial and 
generalized seizures. In addition, Besag t has 
demonstrated that lamotrigine can improve alert- 
ness and cognition, possibly related to a decrease 
in the number of spike and wave events rather 
than overt seizures. This phenomenon has been 
confirmed in adults by Smith et aL 5 who have 
demonstrated improved mastery and happiness 
with the addition of lamotrigine (LTG) to existing 
antiepileptic drug (AED) therapy. As a result of 
these findings, LTG has been used in a group of 
children, adolescents and young adults with 
intellectual and physical disability paying particu- 
lar attention to improvements in seizure control, 
changes in alertness and quality of life, the 
withdrawal of pre-existing AEDs and drug 
side-effects. The present report is an open, 
uncontrolled study reflecting day-to-day clinical 
practice in this particular group of patients. 
PATIENTS AND METHODS 
Thirty-four patients aged 3-26 years with brain 
damage and subsequent epilepsy are reported. 
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All had taken lamotrigine for at least 6 months, 
except six patients in whom LTG was ceased, 
either due to side-effects or a lack of effect. This 
latter was defined as an absence of improvement 
in seizure control over at least 4 months. 
Because of the known interaction between 
lamotrigine and sodium valproate, with the latter 
inhibiting the metabolism of the former, increas- 
ing its half-life and blood levels, LTG was 
introduced slowly. In the first six patients, LTG 
was commenced at a dose of 25 mg every other 
day increasing the dose every 2 weeks. Due to the 
occurrence of a rash in one of these patients, the 
introductory dosage schedule was thereafter 
slowed down. In subsequent 30 patients com- 
menced on the drug, a schedule slower than that 
recommended by the manufacturers was 
employed, commencing with a dose of 12.5 mg 
every third day in patients also taking sodium 
valproate. The dose was increased every 2 weeks 
to: 12.5 mg every second day, 12.5 mg twice daily, 
12.5 mg mane and 25 mg nocte, 25 mg twice daily, 
25 mg mane and 60 mg nocte, 50 mg b.d., 50 mg 
mane and 100 mg nocte, 100 mg twice daily and so 
on. Since the introduction of this slow introduc- 
tory scheme, there have been no rashes and there 
has been no noticeable drowsiness observed. In 
patients not taking sodium valproate, LTG was 
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introduced more rapidly commencing with 
12.5 mg or 25 mg daily, still increasing the dose 
every 2 weeks. 
Seizure control was assessed against baseline 
seizure frequency over the preceding 3-6 months. 
In some patients, especially those with myoclonic 
seizures, the seizures were so frequent hat they 
could not be accurately recorded. Most of the 
patients had intractable seizures and their parents 
or carers had been keeping regular seizure 
records whilst attending the author's clinic. 
Seizure control was assessed as: 
Seizure eradication, no seizures for over 6 
months. 
Ninety per cent seizure reduction, very sporadic 
seizures in patients who were previously having 
numerous (at least daily) seizures. 
Greater than 75% seizure reduction. 
Greater than 50% seizure reduction. 
Less than 50% seizure reduction. 
No effect. 
Deterioration i seizure control. 
The patients were followed up regularly, every 
1 to 2 months, and parents and carers were asked 
about potential drug side-effects bearing in mind 
the difficulty in detecting these in this particular 
patient group. In particular, the frequency of rash 
was sought and signs of carbamazepine (CBZ) 
intoxication usually manifest by diplopia, dizzi- 
ness and ataxia (where applicable), but also 
nausea, vomiting and drowsiness in this particular 
group of patients, due to an interaction with 
LTG 6-8. Improvements in quality of life were 
assessed by parents, carers and physician obser- 
vation and were manifest by improved alertness, 
cognition and general functioning. Whilst this 
approach may appear scientifically 'soft', the 
changes were quite striking, but could not be 
assessed in a quantitative fashion. 
AED blood level monitoring was carried out 
when clinically indicated but LTG concentrations 
were not measured as there is little relationship 
between serum concentrations and seizure 
control 9"]°. Pre-existing AEDs were withdrawn, 
on clinical grounds, where possible. 
RESULTS 
The results are presented firstly for all the 
patients and subsequently for the 15 children, 13 
adolescents and young adults and finally for the 6 
patients in whom LTG therapy was ceased. 
All patients 
There were 34 patients, of whom 19 were male. 
Their mean age was 14.4+6.3 (range, 3-26 
years) and the duration of epilepsy was 12.1 + 6.5 
(range, 0.5-24 years). Excluding the 6 patients in 
whom LTG therapy was ceased, the mean dose of 
LTG was 5.7 + 2.9 (range, 0.8-10.4mg/kg/day 
and the duration of LTG therapy was 1.0 + 0.4 
(range, 0.5-2.0 years). 
The overall results are shown in Table 1 with 
76.6% of patients exhibiting a >50% improve- 
ment in seizure control and 35.3% showing 
complete seizure eradication. At the commence- 
ment of the study, the 34 patients were taking a 
total of 69 AEDs of which 25 (36.2%) were 
withdrawn during the study and nine AEDs 
(13%) were reduced in dosage. With regard to 
side effects, LTG intoxication (overdosage) oc- 
curred in 5 patients, a rash in 1 patient, a 
stroke-like event in 1 patient and marked 
insomnia in a final patient. These side-effects will 
be mentioned in more detail when those patients 
who ceased treatment are dicusssed. 
In terms of quality of life, a demonstrable and 
often quite striking improvement was seen in 22 
of the patients (64.7%). 
Children 
Of the 15 children (14 years of age or younger), 
all the patients howed a >50% improvement in 
seizure control with 40% of the children becom- 
ing seizure free. Three of the patients were 
commenced on LTG monotherapy; two of them, 
twin girls with cerebral palsy, would have been 
commenced on sodium valproate but for pre- 
existing alopecia nd a 4-year-old boy with mild 
cerebral palsy was commenced on LTG for its 
potential cognitive benefits which have been 
realized. 
Eleven AEDs were withdrawn, the more 
Table 1: Overall results in terms of seizure control in 
the 34 patients studied. The number of patients are 
shown in brackets. 
Complete seizure eradication (12) 35.3% 
>90% improvement in seizure control (5) 14.7% 
>75% improvement in seizure conrtrol (5) 14.7% 
>50% improvement in seizure control (4) 11.8% 
<50% improvement in seizure control (1) 2.9% 
No effect, but still taking LTG (1) 2.9% 
No effect, LTG withdrawn (4) 11.8% 
Side effects, LTG withdrawn (2) 5.8% 
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common being clobazam, whilst five AEDs were 
reduced, most frequently sodium valproate. Four 
patients exhibited LTG intoxication due to 
therapeutic overdosage, but no other side-effects 
were observed. Twelve of the children (80%) 
exhibited an improvement in quality of life, 
especially manifest by increased alertness, res- 
ponsiveness and where possible, enhanced speech 
and mobility. 
Adolescents and young adults 
Eleven of the 13 patients (84.6%) showed a 
>50% improvement in seizure control with 46% 
becoming seizure free. One patient has shown a 
slight improvement in seizure control, but is much 
more alert and responsive. The final patient has 
not shown any response and the LTG dose has 
recently been increased. If there is no effect over 
the next few months, LTG will be withdrawn. 
Fourteen AEDs were withdrawn, the most 
common being carbamazepine with four AEDs 
being reduced, especially sodium valproate. One 
patient became intoxicated with LTG, manifest 
by drowsiness, which resolved by halving the dose 
of sodium valproate. Ten of the patients (77%) 
showed an improvement in quality of life 
manifest by increased alertness and functional 
independence. 
Ceased treatment groups 
There were six pateints in this group. Their mean 
age was 15.3 + 5.3 (range, 9-25 years) and they 
had had epilepsy for 13.1 +5.5 (range, 7-24 
years). Four of the patients howed no response 
to LTG over 4-12 months, hence the drug was 
withdrawn. One of these patients developed quite 
marked insomnia which resolved on withdrawing 
LTG. One patient developed a rash within 2 
weeks of introducing LTG. With hindsight and 
subsequent experience, LTG was introduced too 
rapidly. The final patient developed a stroke-like 
illness with a transient left hemiplegia fter four 
doses of 25mg LTG daily. This was not 
associated with any seizures and a cerebral CT 
scan was normal.,Lamotrigine was ceased and the 
signs resolved in 24 hours. Again with experience, 
LTG was introduced too rapidly, and may have 
been the cause of this symptomatology. 
DISCUSSION 
Due to the relatively recent availability of 
lamotrigine and the paucity of data in this 
particular group of patients, the discussion will 
perforce be brief. Seemingly the only existing 
data is an abstract by Hosking et al ~1 who 
reported a >50% decrease in seizure frequency 
over a 12-week period in 35% of 118 children 
with severe developmental bnormalities. These 
authors also observed an improvement in learn- 
ing and behaviour independent of seizure control. 
The present data, albeit open and uncontrolled, 
strongly suggests that lamotrigine is a useful 
antiepileptic drug both as add-on therapy and as 
monotherapy in this particular group of patients 
who often have seizures which are difficult to 
control. Only eight of the 34 patients (23.5%) did 
not show a >50% improverfient in seizure 
control, whilst 35.3% of the patients became 
seizure free and a further 29.5% showed a >75% 
improvement in seizure control. When these 
observations are associated with an improvement 
in quality of life in 64.7% of patients, it is 
proposed that these are quite encouraging results 
in this group of patients. As already mentioned, 
the 'quality of life' assessment was qualitative and 
not quantitative. The changes however were 
striking and very obvious to all involved in the 
patients' management. The present study does 
not contribute to explaining these quite often 
remarkable cognitive changes, but does support 
the observations of Besag ~ and Hosking et al ~, 
that they may occur independent of control of 
overt seizures. Further studies are planned to 
investigate this further in a separate group of 
similar patients. 
Despite the difficulty in assessing side-effects in
this particular group of patients, the side effect 
profile of LTG was excellent. There were two 
patients with significant side-effects; a rash and a 
stroke-like illness, and another patient who 
developed insomnia. Five patients were .LTG 
intoxicated ue to physician over-enthusiasm. In 
all these patients, LTG or VPA dosage reduction 
resolved the problem. 
Also of importance, it was the ability to 
withdraw 36.2% of the original AEDs and reduce 
the dose in a further 13% of AEDs. Based on 
experience in this study and a preceding one ~2, it 
is becoming apparent that it is difficult to 
withdraw sodium valproate in this and other 
patient groups, without a recurrence in seizures. 
The relationship between LTG and VPA seems 
more complex than purely a pharmacokinetic 
interaction and as suggested by Ferrie and 
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Panayiotopoulos 13 there may be a phar- 
macodynamic interaction between these two 
drugs. Whatever the cause, there appears to be a 
therapeutic nteraction between VPA and LTG 
which is beneficial to the patient and allows the 
use of a lower dose of LTG which could be cost 
effective. It may be that the use of VPA and LTG 
in combination represents rational polytherapy. 
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